ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release.

Hua, F., Henstock, P.V., Tang, B.
Journal   Int Immunopharmacol.
Species  
Analytes Measured   HSP27 , JNK , p38 , Rb
Matrix Tested   Cell lysates, Peripheral blood mononuclear cell (PBMC) culture supernatants
Year   2010
Volume  
Page Numbers  
Application   Phosphoproteins
Abstract
Tumor necrosis factor alpha (TNFalpha), a pro-inflammatory factor, plays an important role in many inflammatory diseases. Inhibition of p38 is being pursued as a pharmaceutical treatment to reduce TNFalpha release. Since a variety of cytokines and factors may exist at different amounts in patients, we explored how differences in the cytokine environment impact p38 inhibitor potency. Cytokine co-stimulation with LPS was compared against LPS stimulation alone. In both differentiated U937 cells and peripheral monocytes, GM-CSF co-stimulation with LPS increased TNFalpha release and led to an increased residual TNFalpha levels with p38 inhibitor. Adding MEK inhibitor in the presence of p38 inhibitor further reduced TNFalpha release suggesting that the ERK pathway plays a role in GM-CSF induced reduction of the p38 inhibitor potency. When cells were stimulated with different concentrations of LPS and GM-CSF, the minimal TNFalpha level obtained by MEK inhibitor was not dependent on the stimulation condition; while it was dependent on GM-CSF level for p38 inhibitor. TNFalpha release in the presence of combinations of p38 and MEK inhibitors under different stimulation conditions was measured. A linear model was created using the initial relative ERK and p38 phosphorylation levels and p38 and MEK inhibitor concentrations to accurately predict released TNFalpha level, suggesting these four parameters are sufficient to predict TNFalpha levels. We then used the model to show that with same TNFalpha levels, higher ERK pathway activity reduces p38 inhibitor potency. These results suggest that p38 inhibitor will be a more potent anti-TNFalpha therapy for patients with low ERK pathway activity.

View Publications

Related Products

MAP Kinase Whole Cell Lysate Kit
ERK-1/2, JNK, p38 | Human, Mouse, Rat
Multiplex
Phospho/Total p38 Whole Cell Lysate Kit
p38 | Human, Mouse, Rat
Multiplex
Phospho (Ser608)/Total Rb Whole Cell Lysate Kit
Rb | Human
Multiplex
Phospho (Ser780)/Total Rb Whole Cell Lysate Kit
Rb | Human
Multiplex
Total Rb Whole Cell Lysate Kit
Rb | Human
Singleplex
Phospho-Rb (Ser780) Whole Cell Lysate Kit
Rb | Human
Singleplex
Phospho-Rb (Ser608) Whole Cell Lysate Kit
Rb | Human
Singleplex
MAP Kinase (Total Protein) Whole Cell Lysate Kit
ERK-1/2, JNK, p38 | Human
Multiplex
Phospho/Total JNK Whole Cell Lysate Kit
JNK | Human
Multiplex
Phospho-p38 Whole Cell Lysate Kit
p38 | Human, Mouse, Rat
Singleplex
Phospho-JNK Whole Cell Lysate Kit
JNK | Human, Mouse, Rat
Singleplex
Phospho (Ser82)/Total HSP27 Whole Cell Lysate Kit
HSP27 | Human
Multiplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters